TABLE 1.

Drug susceptibility patterns of 171 clinical M. tuberculosis isolates

Susceptibility or resistance category or drug(s)	Total patients (n = 171)		New patients (n = 97)		Previously treated patients (n = 74)
	No.	% (95% CI)	No.	% (95% CI)	No.	% (95% CI)
Overall susceptibility to first-line drugs	101	59.1 (52.0–66.4)	78	80.4 (72.5–88.3)	23	31.1 (20.5–41.6)
Overall first-line drug resistance	70	40.9 (33.6–48.3)	19	19.6 (11.7–27.5)	51	68.9 (58.4–79.5)
INH	61	35.7 (28.5–42.9)	13	13.4 (6.6–20.2)	48	64.9 (54.0–75.7)
RIF	46	26.9 (20.3–33.6)	7	7.2 (2.1–12.4)	39	52.7 (41.3–64.1)
SM	35	20.5 (14.4–26.5)	13	13.4 (6.6–20.2)	22	29.7 (19.3–40.1)
EMB	17	9.9 (5.5–14.4)	2	2.1a	15	20.3 (11.1–29.4)
PZA	26	15.2 (9.8–20.6)	3	3.1a	23	31.1 (20.5–41.6)
Overall MDR	43	25.2 (18.6–31.7)	6	6.2 (1.4–11.0)	37	50.0 (38.6–61.4)
INH + RIF	10	5.9 (2.3–9.4)	1	1.0a	9	12.1 (4.7–19.6)
INH + RIF + SM	7	4.1 (1.1–7.1)	2	2.1a	5	6.8a
INH + RIF + EMB	1	0.6a	0	0	1	1.4a
INH + RIF + PZA	7	4.1 (1.1–7.1)	0	0	7	9.5 (2.8–16.1)
INH + RIF + SM + EMB	3	1.8a	0	0	3	4.1a
INH + RIF + SM + PZA	4	2.3a	1	1.0a	3	4.1a
INH + RIF + EMB + PZA	4	2.3a	0	0	4	2.3a
INH + RIF + SM + EMB + PZA	7	4.1 (1.1–7.1)	2	2.1a	5	5.4a
Susceptibility to all second-line drugs	152	88.9 (84.2–93.6)	95	98.0a	57	77.0 (67.4–86.6)
Overall second-line drug resistance	19	11.1 (6.4–15.8)	2	2.1a	17	22.9 (13.4–32.6)
CAP	4	2.3a	0	0	4	5.4a
KAN	3	1.8a	0	0	3	4.1a
AKM	2	1.2a	0	0	2	2.7a
OFX	18	10.5 (5.9–15.1)	2	2.1a	16	21.6 (12.2–31.0)
Overall pre-XDR	15	8.7 (4.5–13.0)	1	1.0a	14	14.9 (6.8–23.0)
CAP	4	2.3a	0	0	4	1.4a
KAN	3	1.8a	0	0	3	1.4a
AKM	2	1.2a	0	0	2	0
OFX	14	8.2 (4.1–12.3)	1	1.0a	13	13.5 (5.7–21.3)
Overall XDR	3	1.8a	0	0	3	4.1a
CAP + OFX	1	0.6a	0	0	1	1.4a
CAP + KAN + AKM + OFX	2	1.2a	0	0	2	2.7a

^a95% CI was not determined.